肿瘤抗原特异性CTL细胞联合树突状细胞治疗原发性肝癌的安全性和有效性评价

摘要

Objective To investigate the safety and effectiveness of tumor antigen-specific cytotoxic T lymphocytes (CTL) combined with dendritic cells (DC) for primary hepatocellular carcinoma (HCC).Methods The tumor antigen-specific dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs) were induced from peripheral blood mononuelear cells of patients with HCC in vitro using cytokines such as recombinant human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and so on and then were pulsed with tumor antigen.The tumor antigen specific DC-CTL cells thus obtained were infused back to individual patients.Altogether 30 patients undertook such treatment.The changes of signs and symptomsliver function,AFP,the subsets of lymphocytes in peripheral blood and life quality were assessed after treatment.Results The patients' liver function improved greatly (P ＜ 0.05),the level of AFP decreased significantly(985.2 ng/ml vs 630.7 ng/ml),there were significant differences (P ＜ 0.05).The percentages of CD3 +,CD3 + CD8 +,and CD3 + CD4 + increased remarkably (P ＜ 0.05).The symptoms,signs and quality of life of most patients significantly improved.Conclusions Infusion of tumor antigen-specific DC-CTL cells for patients with advanced primary hepatocellular carcinoma is safe and effective.%目的 探讨肿瘤抗原特异性细胞毒性T淋巴细胞(CTL)联合树突状细胞(DC)输注疗法治疗原发性肝癌的安全性和有效性.方法 采集30例中晚期原发性肝癌患者的外周血单个核细胞,在体外诱导培养成肿瘤抗原特异性的DC细胞和CTL细胞后回输患者体内,观察治疗前后患者的症状体征、肝功能、甲胎蛋白(AFP)、淋巴细胞亚群及生存质量等的变化.结果 DC-CTL治疗后患者的肝功能得到明显改善,AFP下降显著(985.2 ng/mlvs 630.7 ng/ml),差异有统计学意义(P＜0.05).外周血CD3+、CD3+CD8+、CD3+ CD4+淋巴细胞比例明显升高,大部分患者的症状体征明显好转,生存质量提高.结论 中晚期原发性肝癌患者行肿瘤抗原特异性CTL细胞联合DC细胞输注治疗是安全有效的.